睿知中国医院研究地图
候选清单

正在招募肝细胞癌不分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由河南省肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方河南省肿瘤医院Henan Cancer Hospital郑州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06478927,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Patients with histologically or cytologically confirmed unresectable advanced hepatocellular carcinoma;

    入选标准第 3 条

  3. Child-Pugh Liver Function Class: Grade A or B (≤7 points);

    入选标准第 8 条

  4. CNS metastases without clinical symptoms or with clinical symptoms controlled and stabilized for ≥4 weeks after treatment:

    入选标准第 10 条

    Prior treatment with any CDK4/6 inhibitor drug;

    排除标准第 1 条

    Patient has received antitumor therapy in another clinical trial within 4 weeks prior to enrollment;

    排除标准第 2 条

    Patient has undergone a major surgical operation within 4 weeks prior to enrollment or the patient has not fully recovered from such surgical operation;

    排除标准第 3 条

  5. ECOG score 0\~2;

    入选标准第 2 条

  6. An evaluable lesion within 21 days prior to enrollment according to RECIST 1.1 criteria;

    入选标准第 6 条

  7. Other malignant tumors within 5 years (except cured basal cell carcinoma of the skin, carcinoma in situ of the prostate and carcinoma in situ of the cervix);

    排除标准第 7 条

  8. Pregnant or breastfeeding female patients, female patients of childbearing potential with a positive baseline pregnancy test, or patients of childbearing potential who are unwilling to use effective contraception throughout the trial period and for 7 months after the final study dose;

    排除标准第 9 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06478927,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Patients aged ≥18 years and ≤75 years;
  2. ECOG score 0\~2;
  3. Patients with histologically or cytologically confirmed unresectable advanced hepatocellular carcinoma;
  4. Patients who have failed or are intolerant of at least second-line treatment;
  5. Expected survival ≥ 3 months;
  6. An evaluable lesion within 21 days prior to enrollment according to RECIST 1.1 criteria;
  7. Barcelona Clinical Liver Cancer Staging (BCLC staging) stage B or C and not suitable for surgical or local treatment, or progression after surgery or local treatment;
  8. Child-Pugh Liver Function Class: Grade A or B (≤7 points);
  9. HBV DNA quantification must be <500IU/ml or 2500 copies/ml and receive at least 2 weeks of anti-HBV treatment before study entry; HCVRNA quantification-positive patients must have completed antiviral treatment at least 1 month before study entry;
  10. CNS metastases without clinical symptoms or with clinical symptoms controlled and stabilized for ≥4 weeks after treatment:

排除标准:Exclusion Criteria:

  1. Prior treatment with any CDK4/6 inhibitor drug;
  2. Patient has received antitumor therapy in another clinical trial within 4 weeks prior to enrollment;
  3. Patient has undergone a major surgical operation within 4 weeks prior to enrollment or the patient has not fully recovered from such surgical operation;
  4. Severe cardiac disease or discomfort;
  5. Hepatitis B combined with Hepatitis C or Hepatitis D infection;
  6. Patient is allergic to the components of the drug perphenazine or its excipients;
  7. Other malignant tumors within 5 years (except cured basal cell carcinoma of the skin, carcinoma in situ of the prostate and carcinoma in situ of the cervix);
  8. Those with multiple factors affecting the oral administration of drugs (e.g. inability to swallow, post gastrointestinal resection, chronic diarrhea and intestinal obstruction, etc.);
  9. Pregnant or breastfeeding female patients, female patients of childbearing potential with a positive baseline pregnancy test, or patients of childbearing potential who are unwilling to use effective contraception throughout the trial period and for 7 months after the final study dose;
  10. Severe concomitant disease or other co-morbidities that would interfere with planned therapy, or any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation in this study.

引自 ClinicalTrials.gov, NCT06478927, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06478927,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06478927